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Background. Neisseria meningitidis serogroup B (MnB) is a leading cause of invasive meningococcal disease in
adolescents and young adults. A recombinant factor H binding protein (fHBP) vaccine (Trumenba®; bivalent
rLP2086) was recently approved in the United States in individuals aged 10–25 years. Immunogenicity and
safety of 2- or 3-dose schedules of bivalent rLP2086 were assessed in adolescents.
Methods. Healthy adolescents (11 to <19 years) were randomized to 1 of 5 bivalent rLP2086 dosing regimens
(0,1,6-month; 0,2,6-month; 0,2-month; 0,4-month; 0,6-month). Immunogenicity was assessed by serum
bactericidal antibody assay using human complement (hSBA). Safety assessments included local and systemic
reactions and adverse events.
Results. Bivalent rLP2086 was immunogenic when administered as 2 or 3 doses; the most robust hSBA
responses occurred with 3 doses. The proportion of subjects with hSBA titers 1:8 after 3 doses ranged from
91.7% to 95.0%, 98.9% to 99.4%, 88.4% to 89.0%, and 86.1% to 88.5% for MnB test strains expressing
vaccine-heterologous fHBP variants A22, A56, B24, and B44, respectively. After 2 doses, responses ranged from
90.8% to 93.5%, 98.4% to 100%, 69.1% to 81.1%, and 70.1% to 77.5%. Geometric mean titers (GMTs)
were highest among subjects receiving 3 doses and similar between the 2- and 3-dose regimens. After 2 doses,
GMTs trended numerically higher among subjects with longer intervals between the ﬁrst and second dose
(6 months vs 2 and 4 months). Bivalent rLP2086 was well tolerated.
Conclusions. Bivalent rLP2086 was immunogenic and well tolerated when administered in 2 or 3 doses.
Three doses yielded the most robust hSBA response rates against MnB strains expressing vaccine-heterologous
subfamily B fHBPs.
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Neisseria meningitidis serogroup B (MnB) causes most
meningococcal disease in Europe and approximately one
third of cases in the United States [1, 2]. MnB infection is
more common among adolescents and young adults than
the general adult population [2]. MnB polysaccharide vac-
cines are poorly immunogenic, likely due to cross-reacting
epitopes of MnB capsular polysaccharide with polysialic
acid structures on human neuronal cells [3]. Vaccines pro-
duced from MnB outer membrane vesicles have shown
clinical efﬁcacy in children older than 4 years, against
MnB strains bearing antigens homologous to those in
the vaccine, but not against strains expressing antigens
heterologous to the vaccine [4–6]. Therefore, alternative
approaches based on conserved MnB protein antigens
have been pursued to provide protection against diverse
strains causing endemic and epidemic invasive MnB
disease. A recombinant, multicomponent MnB vaccine
(Bexsero, Novartis Vaccines, Siena, Italy) has been licensed
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in the European Union, Canada, Australia [7–9], and, more
recently, in the United States [10].Another multicomponent
vaccine candidate, bivalent rLP2086 (Trumenba®), was re-
cently approved in the United States to prevent invasive me-
ningococcal disease caused by MnB in individuals 10 to 25
years of age [11]. The target antigen for this vaccine,
LP2086, was identiﬁed using a combined biochemical and
functional immunologic screening approach [12].
LP2086 is a bacterial, surface-exposed virulence factor
that binds human factor H, also known as factor H binding
protein (fHBP) [13]. In a comprehensive survey of 1837
MnB strains isolated from patients with invasive disease
in the United States and Europe, the LP2086 gene was
present in all isolates [14], although in rare cases, invasive
disease-causingMnB strains may lack a functional LP2086
gene [15]. LP2086 protein sequences can be grouped into 2
genetically and immunologically distinct subfamilies, des-
ignated A (30% of isolates) and B (70% of isolates) [14].
The bivalent vaccine contains recombinant lipidated pro-
teins from each LP2086 subfamily (bivalent rLP2086),
because this formulation was shown to be most effective at
inducing broadly protective serum bactericidal antibodies.
In phase 1 and 2 studies, immune sera elicited by bivalent
rLP2086 demonstrated bacterial killing activity, measured
in serum bactericidal assays using human complement
(hSBAs), against diverse MnB strains bearing fHBP vari-
ants of both subfamilies and heterologous in sequence to
those in the vaccine [16–19]. For immunogenicity evalua-
tions, 4 MnB test strains were selected to reﬂect the epide-
miology, breadth, and global distribution of MnB strains.
Each hSBA test strain expresses an fHBP variant that is dif-
ferent from vaccine components, thus allowing an objec-
tive assessment of functional and protective bactericidal
immune responses against invasive disease-associated
strains in circulation [20].
This study evaluated the immunogenicity, tolerability,
and safety of bivalent rLP2086 administered in 3-dose or
2-dose regimens in healthy adolescents aged 11 to <19
years at enrollment. The immune response measured by
hSBAwas evaluated 1 month after dose 2 or 3 and included
the percentage of subjects achieving hSBA titers 1:8, a
more conservative indicator of potential seroprotection
than the recognized correlate of protection, an hSBA
titer 1:4 [21, 22]. Safety assessments included the
incidence of local reactions, systemic events, and adverse
events (AEs).
METHODS
Study Participants and Design
This phase 2, multicenter, randomized, single-blind study
was conducted between March 3, 2011 and August 30,
2013, in healthy adolescents 11 to <19 years of age from
the Czech Republic, Denmark, Finland, Germany,
Poland, Spain, and Sweden. Subjects were judged healthy
by the investigator and agreed to practice an effective
form of contraception. Key exclusion criteria were previous
vaccination with any MnB vaccine; previous anaphylactic
reaction to any vaccine or vaccine-related component; his-
tory of culture-proven N meningitidis or Neisseria gonor-
rhoeae disease; pregnancy or nursing; current chronic use
of systemic antibiotics; bleeding diathesis or condition
that would contraindicate intramuscular injection;
known or suspected disease of the immune system or re-
ceipt of immunosuppressive therapy; any neuroinﬂamma-
tory or autoimmune condition; and receipt of any blood
products, including immunoglobulin, within 6 months be-
fore the ﬁrst study vaccination.
Subjects were randomized 3:3:3:2:1 corresponding to a
0,1,6-month, 0,2,6-month, 0,6-month, 0,2-month, and
0,4-month bivalent rLP2086 dosing schedule, respectively
(groups 1–5) (Table 1; Figure 1). The unequal randomiza-
tion schedule reﬂects the comparisons of interest for this
study. The ﬁrst 3 groups (randomized 3:3:3) were assigned
to meet the hypothesis testing objectives; the remaining 2
groups (randomized 2:1) were descriptive and were used
to explore different rLP2086 dosing schedules. Subjects
were randomized using an interactive voice- or web-based
response system. Enrollment was stratiﬁed by age (11 to
<14 and 14 to <19 years) to ensure that all ages were ade-
quately represented in the study. Each subject received
4 study injections, with administration of 2 or 3 doses of
bivalent rLP2086 according to the aforementioned dosing
schedule; saline was administered when bivalent rLP2086
was not scheduled. Participants were blinded to their
assigned dose regimen. All laboratory staff were blinded
to subject, visit, and treatment (ie, randomization group),
but investigators and sponsor knew the allocation of sub-
jects throughout the study. This study was conducted in
accordance with the Declaration of Helsinki [23] and the
International Conference on Harmonisation Guidelines
for Good Clinical Practice [24] (ClinicalTrials.gov:
NCT01299480).
Vaccine and Placebo
Subjects received 1 intramuscular dose of bivalent
rLP2086 or saline in the upper deltoid muscle. Each
0.5-mL dose of bivalent rLP2086 contained 60 µg each
of rLP2086 A (A05) and B (B01) subfamily proteins pro-
duced in Escherichia coli and formulated with aluminum
phosphate in an isotonic buffer in preﬁlled syringes.
Saline (0.9% sodium chloride) was administered as a
0.5-mL dose.
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Immunogenicity Assessments
Blood samples for hSBA were obtained at 0, 2, 3, and 7
months (Table 1). Functional bactericidal antibodies were
assessed against 4 MnB test strains expressing fHBP vari-
ants that are heterologous in sequence compared with the
vaccine components; 2 strains express fHBP subfamily A
variants (A22 and A56), and 2 strains express fHBP sub-
family B variants (B24 and B44). The fHBP variants repre-
sent 4 of the 6 major fHBP variant subgroups that account
for >90% of invasive meningococcal disease isolates circu-
lating in the United States and Europe combined [20]. As
an indication of the diversity of these 4 MnB test strains,
the multilocus sequence type clonal complex (ie, the genetic
background) of each strain represents 1 of the 4 most
prevalent clonal complexes in circulating invasive MnB
strains (Table 2) [20]. Each of these 4 MnB test strains
have detectable fHBP surface expression levels representa-
tive of their respective fHBP variant group, as measured in
a ﬂow cytometry assay adapted from McNeil et al [25]
using the anti-fHBP broadly cross-reactive monoclonal an-
tibody MN86-994-11-1.
The primary immunogenicity endpoints were the pro-
portion of subjects receiving 3 doses of bivalent rLP2086
(vaccination at 0, 1, 6 and 0, 2, 6 months) who achieved
hSBA titer 1:8 for each of the 4 MnB test strains 1
month after the third dose of bivalent rLP2086. An hSBA
titer 1:8 is a more conservative indicator of seroprotec-
tion than a titer 1:4, which is the recognized correlate
Table 1. Study Design
rLP2086, mo
Visit 1*
(Month 0)
Visit 2
(Month 1)
Visit 3*
(Month 2)
Visit 4*
(Month 3)
Visit 5
(Month 6)
Visit 6*
(Month 7)
Visit 7
(Month 12)
Injection 1 Injection 2 Injection 3 Blood Draw Only Injection 4 Blood Draw Only Telephone Contact Only
0,1,6 rLP2086 rLP2086 Saline rLP2086
0,2,6 rLP2086 Saline rLP2086 rLP2086
0,2 rLP2086 Saline rLP2086 Saline
0,4 Saline Saline rLP2086 rLP2086
0,6 rLP2086 Saline Saline rLP2086
Abbreviations: fHBP, factor H binding protein; hSBA, serum bactericidal assay using human complement; rLP2086, bivalent rLP2086 vaccine.
*Blood draw at visits 1, 3, 4, and 6 for hSBA performed with strains expressing fHBP variants A22, A56, B24, and B44.
Figure 1. Subject disposition. *Values in this row used as denominators for percentages.
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of protection against meningococcal disease [21, 22] and
addresses the ability of the hSBA to determine precisely
and accurately a positive from a negative seroresponse.
The hypothesis-testing secondary endpoint was the pro-
portion of subjects receiving 2 doses of bivalent rLP2086
at 0,6 months who achieved hSBA titer 1:8 for each of
the 4 MnB test strains 1 month after the second dose of bi-
valent rLP2086. Other secondary immunogenicity end-
points included assessment of geometric mean titers
(GMTs) for each of the 4 MnB test strains and the propor-
tion of responders with hSBA titers 1:8 for all groups at
each sampling point. Responses after 1 dose of bivalent
rLP2086 were only available for the 0,4-month dosing
group.
Safety Assessments
Subjects were observed for 20 minutes (or longer per
local practice) after vaccination for immediate reactions,
which were documented as AEs. Reactogenicity data
were collected by electronic diary (e-diary) for 7 days
after each injection and included solicited local reactions
and systemic events and use of antipyretic medications.
Injection-site redness and swelling were measured by sub-
jects using calipers provided, and measurements were sub-
sequently graded as mild, moderate, or severe as deﬁned
prospectively by study protocol. Injection-site pain and sys-
temic symptoms of headache, fatigue, chills, vomiting,
diarrhea, muscle pain, and joint pain were graded by the
subjects as mild, moderate, or severe. Temperature was
measured at bedtime; fever was deﬁned as temperature
38.0°C (100.4°F). Only the highest fever measurement
recorded among measurements taken during any single
24-hour period was reported. Unsolicited AEs were collect-
ed from signing of informed consent through 1 month after
the last injection (bivalent rLP2086 or saline). Serious AEs
(SAEs) were collected throughout the study.
Statistical Analysis
The evaluable immunogenicity population included sub-
jects who received all doses of bivalent rLP2086 as ran-
domized, had no major protocol violation or use of
prohibited vaccines, had blood drawn before dose 1 and
1 month after the last dose of bivalent rLP2086, and had
a valid and determinate assay result for the proposed anal-
ysis. The safety population included all participants who
received at least 1 injection (bivalent rLP2086 or saline)
and had any safety data available.
Immunogenicity endpoints, deﬁned as the proportion of
subjects responding with an hSBA titer1:8, were summa-
rized along with the exact 2-sided 95% conﬁdence interval
([CI] or Clopper-Pearson conﬁdence limit) for the propor-
tion; the exact CI for the proportion was computed using
the F distribution. The response rates in subjects receiving 3
versus 2 doses of bivalent rLP2086 were compared with
50% at a signiﬁcance level of 1.25%, using a 1-sided
exact test based on binomial distribution. GMTs were
computed with 2-sided 95% CIs.
RESULTS
Subjects
A total of 1714 subjects were enrolled and 1713 were ran-
domized; 1 subject received saline without randomization
and withdrew from the study (Figure 1). A total of 1712
subjects received at least 1 dose of bivalent rLP2086 or sa-
line, and 1550 (90.5%) completed the study.Most subjects
were white (99.0%) and non-Hispanic (98.5%). At the
time of ﬁrst injection, 63.4% of subjects were 14–18
years of age; mean age of the total population was 14.4
years (Table 3). Demographic characteristics were similar
across dosing regimens.
Immunogenicity
A total of 1450 subjects comprised the evaluable immuno-
genicity population. One month after dose 3, the propor-
tion of subjects with hSBA titers 1:8 after 3 doses of
bivalent rLP2086 administered at 0,1,6 months was
91.7%, 99.4%, 89.0%, and 88.5% for MnB test strains
expressing vaccine-heterologous fHBP variants A22,
A56, B24, and B44, respectively. For subjects vaccinated
at 0,2,6 months, 95.0%, 98.9%, 88.4%, and 86.1% had
hSBA titers 1:8 (Figure 2). There were no signiﬁcant dif-
ferences in immunogenicity among subjects who received
bivalent rLP2086 on the 0,1,6-month and 0,2,6-month
schedules.
Table 2. Genotypic Characteristics of N meningitidis serogroup B Test Strains
Strain ID fHBP Variant (fHBP Peptide IDa) Homology,b % fHBP Subgroup ST Clonal Complex PorA Subtype
PMB2001 A56 (187) 98.1 N1C2 cc213 P1.22,14
PMB2707 B44 (15) 91.6 N4/N5 cc269 P1.19-1,10-4
PMB80 A22 (19) 88.9 N2C2 cc41/44 P1.21,16
PMB2948 B24 (1) 86.2 N6 cc32 P1.12-1,13-1
Abbreviations: fHBP, factor H binding protein; ID, identification; ST, sequence type.
afHBP peptide ID is from http://pubmlst.org/neisseria/fHbp/.
bAmino acid identity to the fHBP subfamily matched vaccine component: A05 for the strains expressing fHBP subfamily A variants, or B01 for the strains expressing
fHBP subfamily B variants. Within fHBP subfamily, the percentage amino acid identity is >83%.
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For fHBP subfamily A strains, among those receiving 2
doses of bivalent rLP2086, >90% of subjects had hSBA ti-
ters 1:8 for A22 and >98% of subjects had hSBA titers
1:8 for A56 1 month after the second dose. For fHBP
subfamily B strains, >69% of subjects had hSBA titers
1:8 for B24 and >70% for B44 (Figure 2). The study de-
sign allowed assessment of hSBA responses at 1 month
after 1 dose of bivalent rLP2086 (0,4-month group only).
After the ﬁrst dose, 55.9%, 67.6%, 56.9%, and 23.8%
of subjects had hSBA titers 1:8 for A22, A56, B24, and
B44, respectively. Prevaccination hSBA responses to all
4 MnB test strains were low, ranging from 5.2% (B44) to
28.1% (A22).
Postvaccination GMTs increased with each dose of biva-
lent rLP2086 and were highest among subjects receiving 3
doses of bivalent rLP2086. For subjects vaccinated at 0,1,6
months, GMTs 1 month after dose 3 were 55.1, 152.9,
29.1, and 40.3 for A22, A56, B24, and B44, respectively.
For subjects vaccinated at 0,2,6 months, GMTs were 56.3,
155.6, 25.6, and 35.0 (Figure 3). For fHBP subfamily A
strains, among subjects receiving 2 doses of bivalent
rLP2086, GMTs ranged from 37.1 to 48.4 for A22, and
104.9 to 125.6 for A56 one month after the second dose.
For the fHBP subfamily B strains, GMTs ranged from 14.7
to 20.6 for B24 and 17.8 to 22.5 for B44. After 2 doses of
bivalent rLP2086, GMTs trended numerically higher
among subjects with a longer interval between doses;
subjects with a 6-month interval between doses (0,6-
month group) had higher GMTs to all 4 MnB test strains
compared with subjects having a 4-month (0,4-month),
2-month (0,2- and 0,2,6-month), or 1-month (0,1,6-
month) interval between doses (Figure 3). After 1 dose
of bivalent rLP2086 (0,4-month group), GMTs were
16.0, 26.8, 12.6, and 6.8, respectively, for A22, A56,
B24, and B44.
Safety
The frequency of local reactions was higher after bivalent
rLP2086 administrations compared with saline; pain at
the injection site was the most common local reaction
(Figure 4). Across dosing schedules, most cases of pain
after bivalent rLP2086 and saline administration were
mild or moderate. Severe pain was reported by 9.9% of
Figure 2. Percentage of subjects with hSBA titers 1:8 against N meningitidis
serogroup B test strains A22, A56, B24, and B44 at baseline and 1 month after
injection with bivalent rLP2086 or saline. Errors shown are 95% conﬁdence inter-
vals. hSBA, human serum bactericidal antibody assay using human complement.
Table 3. Demographics, Safety Population
Bivalent rLP2086 Dosing Schedule
0,1,6 mo
n = 426
0,2,6 mo
n = 414
0,6 mo
n = 451
0,2 mo
n = 277
0,4 mo
n = 144
Total
N = 1712
Sex, n (%)
Female 212 (50) 217 (52) 227 (50) 135 (49) 79 (55) 870 (51)
Male 214 (50) 197 (48) 224 (50) 142 (51) 65 (45) 842 (49)
Race, n (%)
White 423 (99) 408 (99) 448 (99) 272 (98) 144 (100) 1695 (99)
Age at first injection, y, n (%)
11 to <14 155 (36) 154 (37) 164 (36) 101 (37) 53 (37) 627 (37)
14 to <19 271 (64) 260 (63) 287 (64) 176 (64) 91 (63) 1085 (63)
Mean (SD) 14.4 (2.22) 14.4 (2.23) 14.4 (2.17) 14.4 (2.25) 14.3 (2.11) 14.4 (2.20)
Abbreviation: SD, standard deviation.
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subjects who received bivalent rLP2086 and 0.3% sub-
jects who received saline, for each of the 4 injections.
Other common local reactions included redness and swell-
ing, which were mild or moderate in severity (Figure 4).
The mean duration of all local reactions after each dose
of bivalent rLP2086 was 2.1 to 3.2 days; 4 local reactions,
all of which were pain at the injection site, had a duration
greater than 14 days, but no subjects withdrew from the
study due to pain.
Across all injections, the most common systemic events
were headache and fatigue. The majority of systemic events
were mild or moderate in severity. Severe headache was re-
ported by 1.6% of subjects after either bivalent rLP2086
or saline. Severe fatiguewas reported by3.6% of subjects
after either injection (Figure 5). In total, 3 subjects with-
drew due to a systemic event.
Fever 38°C within 7 days of vaccination was infre-
quent, reported by 1.7%–4.3% and 1.5%–2.1% of
bivalent rLP2086 or saline recipients, respectively. Fever
39°C was infrequent (<1% across groups). The median
duration of fever was 1 day after bivalent rLP2086 or saline
administration. Across all 4 injections, 13.6%–16.2% and
7.5%–9.1% of subjects used antipyretic medication after
bivalent rLP2086 and saline, respectively.
During the vaccination phase, 35.5%–37.5%of subjects
reported 1 AE across the 5 dosing groups. Most events
were mild or moderate in severity. The most common AE
was nasopharyngitis (5.5% − 10.1%). Eleven subjects ex-
perienced severe AEs considered to be related to bivalent
rLP2086, including headache, injection-site pain, pyrexia,
vomiting, and injection-site swelling. Two subjects report-
ed SAEs considered to be related to bivalent rLP2086; 1
subject experienced vertigo, chills, and headache after
dose 3, and another experienced pyrexia and vomiting
after dose 1. Overall, there were no differences in the inci-
dence of SAEs between bivalent rLP2086 and saline recip-
ients or between the 3-dose and 2-dose schedules and no
increase in AEs with subsequent dosing. Nineteen subjects
(1.1%) withdrew due to an AE. Of these, 9 AEs were con-
sidered to be related to study vaccination and included
injection-site pain (n = 4), headache (n = 2), migraine,
fatigue, and vertigo (n = 1 each). No deaths were reported.
DISCUSSION
Meningococcal B infection can lead to severe and debilitat-
ing disease. Vaccination against non-B meningococcal
serogroups (ACWY) has proven efﬁcacious in all age
groups, particularly in adolescents who are at high risk
for meningococcal disease [26]. The need for an effective
MnB vaccine is underscored by recent outbreaks on US
college campuses and by endemic infections worldwide
[27–29]. The low basal immunity to meningococcal B
strains in this study emphasizes the vulnerability of adoles-
cents to infection and disease caused by N meningitidis
serogroup B.
In this study, all 5 bivalent rLP2086 vaccination regi-
mens, regardless of schedule or frequency, were immuno-
genic and well tolerated in healthy adolescents. The
2-dose and 3-dose regimens elicited robust immune re-
sponses. Considering that hSBA titers1:4 are an accepted
correlate for protection against invasive meningococcal
disease [21, 22] and that seroprotective responses in this
study were deﬁned using more stringent criteria of hSBA ti-
ters 1:8, bivalent rLP2086 has demonstrated a substan-
tial and broad immune response after 2 doses and a more
robust response after 3 doses, when administered across a
range of dosing schedules. This study also allowed assess-
ment of hSBA responses after 1 dose of bivalent rLP2086.
Figure 3.Geometric mean titers (GMTs) againstNmeningitidis serogroup B test
strains A22, A56, B24, and B44 at baseline and 1 month after injection with
bivalent rLP2086 or saline.
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Figure 4. Local injection-site reactogenicity (recorded by electronic diary [e-diary]). Data have been aggregated across groups to show reactogenicity after each dose.
Figure 5. Systemic reactogenicity (recorded by electronic diary [e-diary]). Data have been aggregated across groups to show reactogenicity after each dose.
*Fever: 38.0–38.4°C =mild; 38.5–38.9°C =moderate; and 39°C = severe.
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After a single vaccination, increased seroprotective
responses compared with baseline against all MnB test
strains were observed.
Among recipients receiving 3 doses of bivalent rLP2086,
the timing of the second vaccination, whether 1 or 2
months after initial vaccination, had no discernable effect
on immunogenicity. Nonetheless, the ability to elicit robust
responses after 2 doses 1 month apart may be valuable dur-
ing outbreaks when timely protection is critical. Immune
responses after 2 doses of bivalent rLP2086 were substan-
tial and indicative of a broad immune response to the MnB
test strains that were selected to represent epidemiological-
ly and antigenically relevant invasive MnB strains.
Immunogenicity generally increased in the 2-dose sched-
ules when there was a longer interval between the ﬁrst
and second dose, as seen by the higher GMTs and generally
higher proportion of subjects with hSBA titers 1:8 after
dose 2 in the 0,6-month dosing regimen compared with
the other dosing schedules. Similar observations were
described for quadrivalent human papillomavirus vaccina-
tion [30, 31]. In these studies, increasing the interval be-
tween doses 2 and 3 from 4 to 10 months resulted in
higher antibody titers against all 4 human papillomavirus
types examined.
Similar to other clinical studies of bivalent rLP2086 in
adolescents and adults [18,19,32,33], the majority of safe-
ty events observed in this study were local reactions and
systemic events that weremild or moderate in severity, tran-
sient, and without potentiation at subsequent dosing.
Approximately two thirds of subjects did not report any
AEs during the study. Overall, 90.6% of subjects were
able to complete their vaccination series, indicating that
vaccinations were well tolerated in adolescents and that
any safety events, such as injection-site pain, were not an
impediment to vaccination. Safety events were not in-
creased in subjects receiving a third dose of bivalent
rLP2086.
CONCLUSIONS
In summary, 2 or 3 doses of bivalent rLP2086 were immu-
nogenic and well tolerated. The 2-dose regimens provided
substantial hSBA responses against diverseMnB strains ex-
pressing fHBP variants heterologous to vaccine antigen.
However, the 3-dose regimens yielded the highest serocon-
version rates against subfamily B strains and a higher level
of hSBA antibodies as measured by GMTs. The conve-
nience of a 2-dose schedule and the potential beneﬁt of
higher level of protective antibodies after a 3-dose schedule
should be carefully considered for future MnB immuniza-
tion schedules.
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